Periodontal Therapeutic Market Research Report – Forecast to 2034

https://www.marketresearchfuture.com/reports/periodontal-therapeutic-market-6562

Market Highlights

Periodontal Therapeutics Market Size is projected to reach USD 0.73 Billion by 2032 exhibiting a compound annual growth rate (CAGR) of 10.3% during the forecast period (2025 - 2034).

Periodontal disease is an infection that occurs around the teeth which include gums, periodontal ligament and alveolar bone. The earliest stage of periodontal is gingivitis infection that affects the gums. Periodontal is mostly caused by bacteria in dental plaque sticky substance that forms on teeth. Although bacterial plaque is the main cause of periodontal disease several other factors such as medication, other diseases, and oral habit also contributes to periodontal disease.  

Periodontal Therapeutics Market Overview and Report Analysis: By Type (Chronic Periodontitis Aggressive Periodontitis and Necrotizing Periodontal), by Treatment (Systematic Antibiotics and Others), by End-Users (Dental Hospital and Others)-Forecast Till 2032

The increasing demand for local antibiotic has resulted in a rise in research and development of local antibiotic. Owing to the increasing incidences of diabetic patients there is a rise in the periodontal therapeutic market. Whereas the rising prevalence of periodontal disorders and technological advancement in therapeutics are some factors positively impacting on the growth of this market. By segment systemic antibiotic will holds the largest share of the market during the forecast period. Whereas local antibiotic segment is expected to grow at the fastest rate due to decreasing chances of formation of resistant bacteria following few side effects. Increasing expenditure on oral health care services by the government especially in developed countries is anticipated to boost the treatment market for the periodontal disorder.

Key Players

Some of the Global Periodontal Therapeutics Market Players are,

Tolmar Inc,

Eli Lilly & Company,

Align Technology Inc.,

Dentsply International,

3M-ESPE,

Ultradent Products Inc.,

Nobel Biocare Holdings AG,

Glidewell Laboratories, Inc.,

Orapharma,

Kaken Pharmaceutical,

Valeant Pharmaceuticals Int. Inc,

Den-Mat Holdings,

Mallinckrodt Pharmaceuticals,

Purdue Pharma L.P.,

Teva Pharmaceutical Industries Limited, and

Fibrocell Sciences Inc.

Segmentation

The global Periodontal Therapeutics Market Research has been segmented on basis of treatment type, types of periodontal and end-users.

• Based on treatment types market is segmented into two segments such as systematic antibiotics and local antibiotics. Systematic antibiotics are further sub-segmented into doxycycline, minocycline, metronidazole, and others. Local antibiotics are further segmented into arestin, chlorhexidine, and others.
• On basis of types of periodontal, the market is segmented into three types such as chronic periodontitis, aggressive periodontitis, necrotizing periodontal disease.
• On basis of end-user market is further is segmented into dental clinics and hospitals
• The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

Regional Analysis

A booming need for more oral hygiene appeal in the field of periodontal treatment is being observed worldwide. The rising awareness regarding oral hygiene and increasing incidence of the periodontal disorder among people are factors responsible for the growth of the Periodontal Therapeutics Market Insights in this region.

The market in the Americas is expected to boost the global periodontal therapeutic market owing to technological advancement and increasing incidences of the periodontal disorder among diabetic patients. According to recent findings from the Centers for Disease Control and Prevention (CDC), half of Americans aged 30 or older have periodontitis, the more advanced form of periodontal disease. This equals approximately 64.7 million Americans. This is largely attributed to the accessibility of an urban healthcare infrastructure. The European market is expected to be the second-largest due to government funding and support from the healthcare sector coupled with the rising prevalence of the periodontal disorder. However, Asia-Pacific is projected to dominate in terms of growth rate over the forecast period owing to rising investment towards R&D activities and unhealthy lifestyle which are resulting in an increased prevalence of obesity. Rising geriatric population and the increasing prevalence of diabetes in this region have a positive influence on the development of the periodontal therapeutic market in this region.  The Middle East and Africa account for the smallest share due to lack of medical technology and poor medical facilities. Emerging economies such as India and China are leading to growth in demand for periodontal therapeutic owing to increasing number of healthcare awareness programs, government investment in healthcare and favorable healthcare insurance coverage. National Oral Health Programmed (NOHP) was conceptualized by the Indian Dental Association to ensure optimal oral health for all by increasing awareness, assuring excellent service and high-quality dental car